Is There a Place for Insulin Pump Therapy in Your Practice?

• Published in: Clinical diabetes Vol. 25; no. 2; pp. 50 - 56
• Main Authors: Skyler, Jay S., Ponder, Steven, Kruger, Davida F., Matheson, Della, Parkin, Christopher G.
• Format: Journal Article
• Language: English
• Published: Alexandria American Diabetes Association 01-04-2007
• Subjects: Care and treatment; Complications and side effects; Diabetes; Forecasts and trends; Health aspects; Hyperglycemia; Hypoglycemia; Insulin pumps; Pumps; Type 1 diabetes; United States
• ISSN: 0891-8929; 1945-4953
• DOI: 10.2337/diaclin.25.2.50

Is There a Place for Insulin Pump Therapy in Your Practice?
Jay S. Skyler , MD, MACP ,
Steven Ponder , MD, FAAP, CDE ,
Davida F. Kruger , MSN, APRN-BC, BC-ADM ,
Della Matheson , RN, CDE and
Christopher G. Parkin , MS
Abstract
IN BRIEF
Insulin pump therapy is becoming a preferred treatment modality of diabetes
specialists for the management of patients with diabetes. As a result,
internists, general practitioners, nurse practitioners, and allied health care
professionals will more frequently encounter patients using, or desiring to
use, these devices. This article serves as an introduction to the principles
that guide patient selection, patient education of self-management skills, and
the practical aspects of pump management that everyone assisting patients on
pump therapy should be aware of.
Footnotes
Jay S. Skyler, MD, MACP, is a professor in the Division of
Endocrinology, Diabetes, and Metabolism and associate director of the Diabetes
Research Institute at the University of Miami Miller School of Medicine in
Florida. Steven Ponder, MD, FAAP, CDE, is medical director of Children's
Diabetes and Endocrine Center at Driscoll Children's Hospital in Corpus
Cristi, Tex. Davida F. Kruger, MSN, APRN-BC, BC-ADM, is a certified nurse
practitioner at the Henry Ford Medical Center—New Center One, Division
of Endocrinology and Metabolism in Detroit, Mich. Della Matheson, RN, CDE, is
a research nurse and nurse specialist at the University of Miami in Florida.
Christopher G. Parkin, MS, is president of CGParkin Communications, Inc., in
Carmel, Ind.
Note of disclosure: Dr. Skyler serves on a speakers
bureau for Novo Nordisk and Sanofi-Aventis; sits on advisory panels for
Animas, Patton Medical, Sanofi-Aventis, Smiths Medical, and Valeritas; is a
stock shareholder in Animas, Medin-go, and Patton Medical; and has received
consulting fees from Eli Lilly, Medingo, Novo Nordisk, Roche Diagnostics,
Sanofi-Aventis, Smiths Medical, and Valeritas. These companies manufacture
insulin pumps, insulin products that can be used in pump therapy, and/or other
insulin delivery systems. Dr. Ponder has received honoraria for speaking
engagements from Animas, which manufactures insulin pumps. Ms. Kruger has
received honoraria from Novo Nordisk, Eli Lilly, and Sanofi-Aventis, all
companies that manufacture insulin products that can be used in pump therapy.
Ms. Matheson has received honoraria or consulting fees from Animas and
Medtronic MiniMed, both of which manufacture insulin pumps. Mr. Parkin has
received consulting fees from Abbott Diabetes Care, Eli Lilly, Sanofi-Aventis,
and Smiths Medical, all of which manufacture insulin pumps or insulin products
that can be used in pump therapy.
American Diabetes Association